<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487211</url>
  </required_header>
  <id_info>
    <org_study_id>ShaheedZABMU</org_study_id>
    <nct_id>NCT03487211</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia</brief_title>
  <acronym>CORTEX</acronym>
  <official_title>Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaheed Zulfiqar Ali Bhutto Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaheed Zulfiqar Ali Bhutto Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs
      has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a
      treatment modality for Fibromyalgia is limited, however small trials have demonstrated its
      efficacy. No head to head comparisons between escitalopram and duloxetine have been
      undertaken. We aim to conduct a single blind, randomized control trial to assess the
      comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly
      diagnosed Fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 drug naive patients with newly diagnosed fibromyalga according to the modified ACR 2016
      criteria shall be enrolled by consecutive sampling after taking written informed consent.
      Baseline severity of fibromyalgia shall be assessed via the Revised Fibromyalgia Impact
      Questionnaire (FIQ-R). They shall be randomized via cluster randomization into two groups.
      The first group shall receive Duloxetine 30mg, will be increased to 60mg after one week. The
      second group shall receive Escitalopram 10mg to be increased to 20mg after one week. Patients
      shall be followed at 0,2,4,8 and 12 weeks. At each visit, any subjective change in symptoms
      shall be noted and the FIQ-R shall be re administered. At the end of the trial, the overall
      change in the FIQ-R from baseline shall be assessed and the difference between both groups
      will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients shall be provided medication with numeric labels</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in FIQ-R (Revised Fibromyalgia Impact Questionnaire) from baseline</measure>
    <time_frame>4,8 and 12 weeks</time_frame>
    <description>Percentage decrease in FIQ-R from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Duloxetine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily</description>
    <arm_group_label>Duloxetine Group</arm_group_label>
    <other_name>DUPREX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily</description>
    <arm_group_label>Escitalopram Group</arm_group_label>
    <other_name>EXAPRO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drug Naive patients

          -  Newly diagnosed with FIbromyalgia according to Modified ACR 2016 criteria

        Exclusion Criteria:

          -  Concomitant depression/bipolar disorder or any other documented psychiatric illness

          -  Autoimmune disorders (SLE, RA)

          -  Peripheral Neuropathic pain due to any cause

          -  Uncontrolled hypertension

          -  Impaired renal or hepatic functions (on Lab assay)

          -  Chronic infections (e.g.Tuberculosis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad A Arif, MRCP, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Zulfiqar Ali Bhutto Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pakistan Institute of Medical Sciences</name>
      <address>
        <city>Islamabad</city>
        <state>Islamabad Capital Territory</state>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009 Jun;36(6):1304-11. doi: 10.3899/jrheum.081090. Epub 2009 Apr 15.</citation>
    <PMID>19369473</PMID>
  </results_reference>
  <results_reference>
    <citation>Wright CL, Mist SD, Ross RL, Jones KD. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol. 2010 Sep;6(5):745-56. doi: 10.1586/eci.10.64. Review.</citation>
    <PMID>20828282</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith HS, Bracken D, Smith JM. Pharmacotherapy for fibromyalgia. Front Pharmacol. 2011 Mar 31;2:17. doi: 10.3389/fphar.2011.00017. eCollection 2011.</citation>
    <PMID>21772818</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaheed Zulfiqar Ali Bhutto Medical University</investigator_affiliation>
    <investigator_full_name>DR. MOHAMMAD ALI ARIF</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia treatment</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

